IntelliProve key facts
as of Oct 2026- Developer of a healthcare platform designed for determining vital health parameters.
- IntelliProve is valued at approximately $3.3M as of Oct 2026 (last reported valuation).
- It has raised $2.4M; the latest was Seed Round ($1.3M) in Jan 2025.
- Notable investors include Imec.istart, Gilles Mattelin, Jorn Vanysacker, Matthias Geeroms, Jeroen De Wit — 13 tracked in total.
- Status: Privately Held (backing).
IntelliProve's last reported valuation, Nov 2022. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch IntelliProve: the Monday email on marks, rounds and moves
IntelliProve funding rounds
No funding rounds for IntelliProve are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs IntelliProve
13+IntelliProve valuation
IntelliProve's last reported valuation was $3.3 million in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.
IntelliProve investors
13 investors are on record for IntelliProve, including Imec.istart, Gilles Mattelin, Jorn Vanysacker and Matthias Geeroms.
About IntelliProve
Developer of a healthcare platform designed for determining vital health parameters. The company's platform offers artificial intelligence-driven health monitoring technology that measures physiological and mental health parameters without the need for a medical device or wearable and by using a smartphone camera that is based on a combination of novel signal processing and computer vision technology, enabling patients to assess health within seconds.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2021
- Employees
- 21
- Website
- intelliprove.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.